Cargando…

Agomelatine: a potential novel approach for the treatment of memory disorder in neurodegenerative disease

Agomelatine is a selective agonist of melatonin receptor 1A/melatonin receptor 1B (MT(1)/MT(2)) and antagonist of 5-hydroxytryptamine 2C receptors. It is used clinically to treat major depressive episodes in adults. The pro-chronobiological activity of agomelatine reconstructs sleep-wake rhythms and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Qiang, Li, Tian, Liu, Guo-Wei, Zhang, Yan-Li, Guo, Jun-Hong, Wang, Zhao-Jun, Wu, Mei-Na, Qi, Jin-Shun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700086/ https://www.ncbi.nlm.nih.gov/pubmed/36204828 http://dx.doi.org/10.4103/1673-5374.353479

Ejemplares similares

Agomelatine: A Potential Multitarget Compound for Neurodevelopmental Disorders
por: Savino, Rosa, et al.
Publicado: (2023)

Profile of agomelatine and its potential in the treatment of generalized anxiety disorder
por: Levitan, Michelle Nigri, et al.
Publicado: (2015)

Agomelatine: A novel melatonergic antidepressant
por: Manikandan, S
Publicado: (2010)

Agomelatine for the Treatment of Generalized Anxiety Disorder: A Meta-Analysis
por: Wang, Sheng-Min, et al.
Publicado: (2020)

Agomelatine and its therapeutic potential in the depressed patient
por: Kennedy, Sidney H, et al.
Publicado: (2007)

Potentiation of Antidepressant Effects of Agomelatine and Bupropion by Hesperidin in Mice
por: Nadar, Jegan Sakthivel, et al.
Publicado: (2018)

Efficacy and safety of agomelatine in the treatment of patients with depressive disorder: A meta-analysis
por: Guo, Yue-Han, et al.
Publicado: (2023)

Agomelatine for postpartum depression and breastfeeding
por: Xiao, Le
Publicado: (2021)

Scaffold Hopping Toward Agomelatine: Novel 3, 4-Dihydroisoquinoline Compounds as Potential Antidepressant Agents
por: Yang, Yang, et al.
Publicado: (2016)

Agomelatine in the Treatment of Major Depressive Disorder: An Assessment of Benefits and Risks
por: Gahr, Maximilian
Publicado: (2014)

Evidence-Based Pharmacotherapy of Generalised Anxiety Disorder: Focus on Agomelatine
por: Stein, Dan J.
Publicado: (2021)

Novel Conformationally Constrained Analogues of Agomelatine as New Melatoninergic Ligands
por: Rami, Marouan, et al.
Publicado: (2012)

Evaluation of the Highly Variable Agomelatine Pharmacokinetics in Chinese Healthy Subjects to Support Bioequivalence Study
por: Pei, Qi, et al.
Publicado: (2014)

Agomelatine prevents angiotensin II-induced endothelial and mononuclear cell adhesion
por: Hong, Najiao, et al.
Publicado: (2021)

Efficacy and tolerability of agomelatine in the treatment of depression
por: Plesničar, Blanka Kores
Publicado: (2014)

Agomelatine Efficacy in the Night Eating Syndrome
por: Milano, Walter, et al.
Publicado: (2013)

Case report: Hypnic headache responds to agomelatine–a potential prophylactic treatment option
por: Xu, Sui-yi, et al.
Publicado: (2023)

Agomelatine in the treatment of depressive disorders in clinical practice: multicenter observational CHRONOS study
por: Ivanov, Stanislav V, et al.
Publicado: (2014)

The Melatonergic System in Mood and Anxiety Disorders and the Role of Agomelatine: Implications for Clinical Practice
por: De Berardis, Domenico, et al.
Publicado: (2013)

Venlafaxine augmentation with agomelatine in a patient with obsessive-compulsive disorder and suicidal behaviors
por: Signorelli, Maria S, et al.
Publicado: (2014)

Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action
por: Millan, Mark J.
Publicado: (2022)

Agomelatine in the treatment of anhedonia, somatic symptoms, and sexual dysfunction in major depressive disorder
por: Huang, Juan, et al.
Publicado: (2023)

A pilot study on improvements in attention function in major depressive disorder after 12 weeks of escitalopram monotherapy or combined treatment with agomelatine
por: Li, Zhe, et al.
Publicado: (2023)

Agomelatine: The evidence for its place in the treatment of depression
por: Eser, Daniela, et al.
Publicado: (2010)

The Effect of Agomelatine in Behavioral and Psychological Symptoms of Dementia
por: Wang, Carol Sheei-Meei, et al.
Publicado: (2022)

Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial
por: Kang, Ruiying, et al.
Publicado: (2015)

Effect of agomelatine on memory deficits and hippocampal gene expression induced by chronic social defeat stress in mice
por: Martin, Vincent, et al.
Publicado: (2017)

Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece
por: Maniadakis, Nikos, et al.
Publicado: (2013)

Evidence-Based Pharmacotherapy of Anxiety Symptoms in Patients with Major Depressive Disorder: Focus on Agomelatine
por: Stein, Dan J.
Publicado: (2023)

Additional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting
por: Lee, Kyung Ho, et al.
Publicado: (2023)

Novel Microglia-based Therapeutic Approaches to Neurodegenerative Disorders
por: Zhang, Lijuan, et al.
Publicado: (2023)

Sub-Acute Oral Toxicity of a Novel Derivative of Agomelatine in Rats in a Sex-Dependent Manner
por: Yang, Qiushi, et al.
Publicado: (2019)

Agomelatine: relief ensured at each and every stage of depression
por: Möller, Hans-Jurgen
Publicado: (2010)

A systematic review of agomelatine-induced liver injury
por: Freiesleben, Silka Dawn, et al.
Publicado: (2015)

Inhibitory effect of celecoxib on agomelatine metabolism in vitro and in vivo
por: He, Jiayang, et al.
Publicado: (2018)

Assessing the therapeutic potential of agomelatine, ramelteon, and melatonin against SARS-CoV-2
por: Yadalam, Pradeep Kumar, et al.
Publicado: (2022)

The emergence of new antidepressants for clinical use: Agomelatine paradox versus other novel agents
por: Fasipe, Olumuyiwa John
Publicado: (2019)

Agomelatine Augmentation of Escitalopram Therapy in Treatment-Resistant Obsessive-Compulsive Disorder: A Case Report
por: De Berardis, Domenico, et al.
Publicado: (2012)

Agomelatine beyond Borders: Current Evidences of Its Efficacy in Disorders Other than Major Depression
por: De Berardis, Domenico, et al.
Publicado: (2015)

A network pharmacology-based approach to explore the therapeutic potential of Sceletium tortuosum in the treatment of neurodegenerative disorders
por: Luo, Yangwen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m49p6ggndvm7ekg87bf61isksl